Ondine Biomedical Inc. is dedicated to the development of non-antibiotic
anti-infective therapies for a broad spectrum of bacterial, viral and fungal infections. We are focused on the development and commercialization of our patented light activated technology, photodisinfection. Photodisinfection provides rapid antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance
Ondine currently has numerous applications of its photodisinfection technology at various stages of development. Our Company’s lead product is the MRSAid™ nasal decolonization system which is used to decolonize the nares of methicillin-resistant Staphylococcus aureus (MRSA). Other medical applications and next generation products in the hospital acquired infection market are currently under development.
Photodisinfection was first commercialized in April 2006 when Ondine launched Periowave™, an adjunctive therapy for the treatment of chronic adult periodontitis (gum disease). In June 2009 Ondine sold its Dental Healthcare Business to PDT Inc., completing the product’s journey from the lab all the way to a successful enterprise supported by a strategic partner. Ondine is a private company. It was formerly a public company listed on the TSX and the AIM market of the London Stock Exchange. We are headquartered in Vancouver, Canada, and have a research and development facility in Bothell, Washington, USA and an International office in St. Michael, Barbados.